GO:0000380 alternative mRNA splicing, via spliceosome: Spliceosome-Mediated Exon Selection, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0000380 describes the biological process of generating multiple mature mRNAs from one primary transcript by differential exon use, carried out by the spliceosome.
• The spliceosome is a dynamic ribonucleoprotein machine that recognizes splice sites and catalyzes intron removal and exon ligation.
• Alternative splicing expands proteome diversity and is regulated by cis-elements, trans-acting splicing factors, and co-transcriptional coupling.
• Dysregulated alternative splicing contributes to cancer progression, chemoresistance, metabolic disease, and neurodegeneration.
• Core and auxiliary splicing factors such as SF3B3, SNRPA, BCAS2, and WAC are experimentally tractable entry points for functional studies.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of splicing factor function and splice isoform relevance.
Description
Alternative mRNA splicing, via spliceosome (GO:0000380) is the biological process in which a single pre-mRNA is processed into multiple mature mRNA isoforms through differential selection of exons and splice sites. This process is executed by the spliceosome, a highly dynamic ribonucleoprotein complex that assembles on each intron, recognizes the 5-prime splice site, branch point, polypyrimidine tract, and 3-prime splice site, and catalyzes two sequential transesterification reactions to remove introns and join exons. Because most human multi-exon genes undergo some form of alternative splicing, this process is a central mechanism for expanding transcriptomic and proteomic diversity from a limited genome. For researchers, GO:0000380 is important because it connects molecular machines to physiological and pathological outcomes. Spliceosome-mediated alternative splicing influences cell proliferation, differentiation, metabolic signaling, and stress responses, and its perturbation is increasingly linked to cancer, neurodegeneration, and endocrine dysfunction. Mechanistic studies have shown that specific splicing factors can control isoform switches in key disease genes; for example, SF3B3-regulated mTOR alternative splicing promotes colorectal cancer progression and metastasis, and m6A-modified SNRPA controls ERCC1 exon 8 alternative splicing to induce cisplatin resistance in lung adenocarcinoma. Methodologically, GO:0000380 is studied with a combination of transcriptome-wide sequencing, targeted isoform assays, spliceosome assembly biochemistry, and CRISPR-based perturbation. The sections below summarize the definition, core stages, key genes, disease links, and experimental models relevant to this GO term, using only verified literature and the QuickGO definition as the factual basis.
alternative mRNA splicing, via spliceosome At A Glance
| GO ID | GO:0000380 |
|---|---|
| GO term | alternative mRNA splicing, via spliceosome |
| Ontology | biological_process |
| Synonym | alternative nuclear mRNA splicing, via spliceosome; splice site selection |
| Major function | Generation of multiple mature mRNA isoforms from a single primary transcript by differential exon use via the spliceosome |
| Cellular context | Nucleus, co-transcriptional and post-transcriptional pre-mRNA processing |
| Key machinery | Spliceosome (snRNPs U1, U2, U4/U6, U5 and associated proteins) |
| Regulatory inputs | Cis-acting splicing enhancers/silencers, trans-acting splicing factors, RNA modifications, signaling pathways |
| Disease relevance | Cancer, chemoresistance, neurodegeneration, metabolic and endocrine disorders |
What Is GO:0000380?
In plain terms, GO:0000380 describes how a cell takes one newly made pre-mRNA and produces several different mature mRNAs by choosing different combinations of exons. The QuickGO definition states that it is the process of generating multiple mRNA molecules from a given set of exons by differential use of exons from the primary transcript(s) to form multiple mature mRNAs that vary in their exon composition. This process occurs via the spliceosome and is also referred to as alternative nuclear mRNA splicing, via spliceosome, or splice site selection.
Why Is alternative mRNA splicing, via spliceosome Important in Cell Biology?
GO:0000380 is important because spliceosome-mediated alternative splicing is a major source of transcript and protein diversity and a key regulatory layer in eukaryotic gene expression. It enables cells to respond to developmental and environmental cues by switching isoform expression without changing the genome, and it is tightly coupled to transcription, RNA modification, and RNA quality control. When this process is misregulated, the resulting isoform imbalances can drive tumor progression, drug resistance, and neuronal dysfunction, making the spliceosome and its accessory factors attractive targets for mechanistic and therapeutic research.
• Expands proteome diversity by producing multiple mRNA isoforms from one gene.
• Controls tissue-specific and developmental isoform programs through regulated splice site selection.
• Couples transcription with pre-mRNA processing and RNA modification status.
• Regulates key signaling genes such as mTOR through isoform switching.
• Modulates DNA repair capacity via ERCC1 exon 8 splicing and contributes to cisplatin resistance.
• Supports endocrine functions such as insulin synthesis and secretion through BCAS2-dependent splicing.
• Is linked to Alzheimer's disease and other neurodegenerative conditions through altered splicing patterns.
• Provides a mechanistic basis for understanding mitophagy regulation via WAC nuclear condensates.
• Offers a large set of druggable and CRISPR-tractable splicing factors for functional genomics.
What Happens During alternative mRNA splicing, via spliceosome?
Spliceosome assembly on the pre-mRNA
In simple terms: The spliceosome is built step by step on each intron, like a molecular machine that reads the boundaries of the intron.
Spliceosome-mediated splicing begins with recognition of the 5-prime splice site by U1 snRNP and the branch point and polypyrimidine tract by SF1 and U2AF, followed by recruitment of U2 snRNP to the branch point. This early recognition establishes the exon-intron architecture and is influenced by cis-acting elements and trans-acting splicing factors that modulate splice site strength. In Saccharomyces cerevisiae, many of these assembly principles are conserved and have been dissected genetically, providing a mechanistic framework for understanding human spliceosome function.
Catalytic activation and exon ligation
In simple terms: After assembly, the spliceosome cuts out the intron and joins the exons together in two chemical steps.
The assembled spliceosome undergoes rearrangements that position the 5-prime splice site and branch point for the first transesterification, forming a lariat intermediate, followed by a second transesterification that ligates the exons and releases the intron lariat. These catalytic steps are mediated by the RNA components and associated proteins of the spliceosome, and their fidelity determines the exon composition of the mature mRNA. Alternative splicing arises when these steps are directed to different splice site pairs, producing distinct exon combinations from the same primary transcript.
Exon definition and stepwise decisions
In simple terms: The cell decides which exons to include by defining exon boundaries in a coordinated, stepwise manner.
Coordinated alternative splicing decisions can be described by stepwise exon definition, in which recognition of one exon influences the inclusion or skipping of adjacent exons. This model helps explain how multiple splicing decisions within a transcript are coupled rather than independent, and how regulatory factors can shift isoform ratios in a coordinated way. Such stepwise logic is central to understanding how spliceosome-mediated alternative splicing generates reproducible isoform patterns across cell types and conditions.
Co-transcriptional coupling and RNA modification
In simple terms: Splicing often happens while the RNA is still being made, and chemical marks on the RNA can change the outcome.
Alternative splicing is frequently co-transcriptional, meaning that spliceosome assembly and catalysis occur on nascent transcripts and can be influenced by transcription elongation and chromatin state. RNA modifications such as m6A can modulate splicing decisions by recruiting or excluding splicing factors; for example, m6A-modified SNRPA controls ERCC1 exon 8 alternative splicing and contributes to cisplatin resistance in lung adenocarcinoma. These layers of regulation allow the cell to integrate transcriptional and post-transcriptional signals into a single isoform output.
Regulation by signaling and condensates
In simple terms: Signaling pathways and reversible molecular assemblies can tune how splicing factors choose splice sites.
Signaling pathways and nuclear organization can regulate alternative splicing outcomes. Nuclear condensates of WW domain-containing adaptor with coiled-coil (WAC) regulate mitophagy via alternative splicing, illustrating how phase-separated compartments can influence splice site selection. In cancer, SF3B3-regulated mTOR alternative splicing promotes colorectal cancer progression and metastasis, showing that specific splicing factors can couple growth signaling to isoform switches. Together, these examples demonstrate that GO:0000380 is not a constitutive housekeeping process but a regulated decision point responsive to cellular state.
Key Genes Involved in GO:0000380 alternative mRNA splicing, via spliceosome
The following genes and proteins represent core spliceosome components and auxiliary splicing regulators that have been experimentally linked to alternative mRNA splicing, via spliceosome (GO:0000380) in the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SF3B3 | Spliceosome component involved in branch point recognition and alternative splicing regulation | Regulates mTOR alternative splicing and promotes colorectal cancer progression and metastasis |
| SNRPA | U1 snRNP component involved in 5-prime splice site recognition | m6A-modified SNRPA controls ERCC1 exon 8 alternative splicing and cisplatin resistance |
| BCAS2 | Spliceosome-associated factor involved in pre-mRNA splicing | Participates in insulin synthesis and secretion via mRNA alternative splicing in mice |
| WAC | WW domain-containing adaptor with coiled-coil that forms nuclear condensates | Regulates mitophagy via alternative splicing through nuclear condensates |
| U1 snRNP components | Recognize the 5-prime splice site during early spliceosome assembly | Core machinery for splice site selection and alternative splicing |
| U2 snRNP components | Recognize the branch point and support catalytic activation | Central to spliceosome assembly and exon definition |
| U4/U6 and U5 snRNPs | Form the tri-snRNP and contribute to catalytic core rearrangements | Required for spliceosome activation and catalysis |
| SF1 | Recognizes the branch point during early spliceosome assembly | Helps define intron boundaries and alternative splice sites |
| U2AF | Binds the polypyrimidine tract and 3-prime splice site region | Essential for 3-prime splice site selection and alternative splicing |
| SR proteins | Sequence-specific splicing activators that recruit spliceosome components | Modulate exon inclusion and are commonly deregulated in disease |
| hnRNP proteins | Sequence-specific splicing repressors and RNA-binding regulators | Antagonize SR proteins and shape isoform ratios |
| Spliceosome-associated helicases | ATP-dependent RNA rearrangements during spliceosome activation and catalysis | Required for proofreading and catalytic steps |
| Prp proteins (yeast) | Conserved spliceosome subunits and assembly factors | Model system for mechanistic dissection of splicing |
| m6A writer/reader components | Deposit and interpret RNA methylation marks that influence splicing | Link RNA modification to alternative splicing decisions |
| Signaling kinases (e.g., mTOR pathway components) | Transmit growth and stress signals to splicing regulators | Connect signaling state to isoform switching |
| Nuclear condensate proteins | Organize splicing factors into membraneless compartments | Influence splice site selection and mitophagy regulation |
| ERCC1 splicing regulators | Control exon 8 inclusion in ERCC1 pre-mRNA | Modulate DNA repair capacity and cisplatin sensitivity |
How Is alternative mRNA splicing, via spliceosome Regulated?
Alternative mRNA splicing, via spliceosome is regulated at multiple levels. Cis-acting splicing enhancers and silencers in the pre-mRNA recruit or repel trans-acting factors such as SR proteins and hnRNP proteins, thereby influencing splice site choice. RNA modifications, including m6A, can alter the binding of splicing regulators and change isoform ratios, as shown for SNRPA-dependent ERCC1 exon 8 splicing. Signaling pathways can also impinge on splicing; SF3B3-regulated mTOR alternative splicing links growth signaling to isoform switches in colorectal cancer. In addition, nuclear organization and condensate formation, exemplified by WAC nuclear condensates, can modulate alternative splicing outcomes. These regulatory layers allow the cell to integrate transcriptional, post-transcriptional, and signaling inputs into a defined isoform program.
alternative mRNA splicing, via spliceosome and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SF3B3 | Colorectal cancer progression and metastasis via mTOR alternative splicing | Knockout or knockdown in colorectal cancer cell lines followed by isoform and metastasis assays |
| SNRPA | Cisplatin resistance in lung adenocarcinoma via ERCC1 exon 8 splicing | Point mutation or knockout in lung adenocarcinoma cells with cisplatin sensitivity readouts |
| BCAS2 | Insulin synthesis and secretion defects in mice | Knockout or conditional knockout mouse models with glucose and insulin measurements |
| WAC | Mitophagy regulation via alternative splicing and nuclear condensates | Knockout or tagged knock-in in cell lines with mitophagy flux assays |
| Splicing factors in Alzheimer's disease | Neurodegeneration and altered isoform patterns | Knockout or overexpression in neuronal cell models with isoform sequencing |
Cancer progression and chemoresistance
Dysregulated alternative splicing is a hallmark of cancer, where isoform switches can promote proliferation, invasion, and therapy resistance. SF3B3-regulated mTOR alternative splicing promotes colorectal cancer progression and metastasis, indicating that spliceosome components can act as oncogenic drivers. In lung adenocarcinoma, m6A-modified SNRPA controls ERCC1 exon 8 alternative splicing to induce cisplatin resistance, linking splicing regulation directly to chemotherapy response. These findings support the view that GO:0000380-related factors are potential therapeutic targets and biomarkers in oncology.
Neurodegeneration and Alzheimer's disease
Alternative splicing changes are increasingly recognized in neurodegenerative disorders, including Alzheimer's disease, where altered isoform patterns can affect neuronal function and disease progression. Because spliceosome-mediated splicing is essential for neuronal gene expression, perturbations in splicing factors or their regulation may contribute to synaptic dysfunction and neurodegeneration. Studying GO:0000380 in neuronal models can help identify isoform changes that precede or accompany disease pathology.
Metabolic and endocrine dysfunction
Spliceosome-mediated alternative splicing also contributes to metabolic and endocrine physiology. BCAS2 participates in insulin synthesis and secretion via mRNA alternative splicing in mice, demonstrating a role for splicing regulation in pancreatic beta cell function. This link suggests that splicing factor dysfunction could contribute to diabetes and related metabolic disorders, and that GO:0000380 is relevant beyond oncology.
Mitophagy and cellular stress responses
Alternative splicing can regulate stress responses such as mitophagy. Nuclear condensates of WAC regulate mitophagy via alternative splicing, showing that splicing decisions can control mitochondrial quality control. This connection broadens the disease relevance of GO:0000380 to conditions involving mitochondrial dysfunction and cellular stress.
From alternative mRNA splicing, via spliceosome-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a splicing factor required for a specific alternative splicing event? | CRISPR knockout or knockdown in a relevant cell line followed by isoform-specific RT-PCR or RNA-seq |
| Does a specific amino acid residue in a splicing factor control splice site selection? | Point mutation knock-in at the endogenous locus with isoform readouts |
| Does a disease-associated isoform cause a phenotype? | Knock-in of the isoform-specific sequence or minigene reporter assays |
| Where does a splicing factor localize and assemble? | Tagged knock-in with fluorescent or affinity tags followed by imaging or proteomics |
| Does overexpression of a splicing factor drive transformation or resistance? | Overexpression cell models with proliferation, migration, and drug sensitivity assays |
| Does a splicing regulator affect organismal physiology? | Conditional knockout or transgenic mouse models with metabolic or neurological phenotyping |
How to Study the alternative mRNA splicing, via spliceosome Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Genome-wide transcript levels and splice junction usage | Identify alternative splicing events and isoform switches |
| Long-read isoform sequencing | Full-length transcript isoforms | Define exon composition of mature mRNAs |
| Isoform-specific RT-PCR | Relative abundance of specific splice isoforms | Validate candidate splicing events |
| Minigene reporter assay | Splicing of a defined exon-intron construct | Test cis-elements and trans-acting factors |
| CLIP or related RNA-protein methods | Binding sites of splicing factors on RNA | Map direct targets of splicing regulators |
| Spliceosome assembly assays | snRNP recruitment and complex formation | Dissect stepwise assembly and catalysis |
| Fluorescence imaging | Localization and condensate formation of splicing factors | Study nuclear organization and splicing regulation |
| Proteomics | Protein interactions and post-translational modifications | Identify spliceosome-associated complexes and regulators |
Transcriptome-wide isoform profiling
RNA-seq and long-read isoform sequencing are used to quantify alternative splicing events and identify isoform switches associated with GO:0000380. These methods can detect exon skipping, alternative 5-prime and 3-prime splice sites, and intron retention, and are often combined with differential expression analysis to link splicing factors to their targets. In disease studies, isoform profiling of patient-derived or model cell lines can reveal splicing signatures associated with progression or drug resistance.
Targeted isoform and splice site assays
Isoform-specific RT-PCR, minigene reporters, and splice site mapping are used to validate specific alternative splicing events. These assays are essential for confirming that a candidate splicing factor directly regulates a given exon, as shown for SF3B3-dependent mTOR splicing and SNRPA-dependent ERCC1 exon 8 splicing. Stepwise exon definition models can be tested with minigene constructs that vary exon and intron architecture.
Spliceosome assembly and RNA-protein interaction methods
Biochemical and crosslinking-based methods can monitor spliceosome assembly and RNA-protein interactions on pre-mRNA. These approaches help define which snRNPs and accessory factors are recruited to a given splice site and how assembly is perturbed by mutations or regulatory signals. In yeast, genetic and biochemical dissection of spliceosome assembly provides a conserved framework for interpreting human data.
Imaging and condensate analysis
Fluorescence imaging of tagged splicing factors and condensate markers can reveal spatial organization of splicing regulators, as illustrated by WAC nuclear condensates that regulate mitophagy via alternative splicing. Live-cell imaging and FRAP can assess condensate dynamics and their relationship to splice site selection. Combining imaging with isoform readouts helps connect nuclear organization to GO:0000380 outcomes.
How CRISPR Can Be Used to Study GO:0000380 alternative mRNA splicing, via spliceosome
Knockout
CRISPR knockout of splicing factor genes is used to test whether a candidate factor is required for specific alternative splicing events and downstream phenotypes. For example, knockout or knockdown of SF3B3 can reduce mTOR alternative splicing and impair colorectal cancer progression and metastasis in model systems. Similarly, loss of SNRPA function can alter ERCC1 exon 8 splicing and change cisplatin sensitivity in lung adenocarcinoma cells. Knockout models are therefore a primary tool for causal testing of GO:0000380-related genes.
Point Mutation
Point mutation knock-in allows precise testing of residues or regulatory sites within splicing factors or splice site elements. By introducing disease-associated or phospho-site mutations at the endogenous locus, researchers can determine whether a specific molecular feature is required for splice site selection and isoform output. Such models are particularly useful when complete knockout is lethal or when domain-specific functions need to be separated.
Knock-in
Knock-in strategies can be used to tag endogenous splicing factors for imaging or affinity purification, or to express specific isoforms and minigenes. Tagged knock-in of WAC, for example, supports studies of nuclear condensate formation and mitophagy regulation via alternative splicing. Isoform-specific knock-in can also test whether a particular splice variant is sufficient to drive a phenotype.
Overexpression
Overexpression models are used to test whether increased levels of a splicing factor or isoform are sufficient to promote transformation, drug resistance, or metabolic changes. Overexpression of SF3B3 or its regulated mTOR isoform can enhance colorectal cancer cell phenotypes, while overexpression of SNRPA-related splicing programs can modulate cisplatin response. These models complement loss-of-function studies by establishing sufficiency in GO:0000380-driven phenotypes.
How EDITGENE Supports alternative mRNA splicing, via spliceosome Research
Researchers studying alternative mRNA splicing, via spliceosome-related genes often need to determine whether a candidate gene is causally involved in a specific isoform switch, disease phenotype, or drug response. Establishing causality requires precise genetic models that can remove, modify, tag, or overexpress the gene or its regulatory elements in relevant cell types. EDITGENE provides a suite of CRISPR-based services designed to support such mechanistic studies of GO:0000380 and its associated factors.
Contact EDITGENE today to design your custom CRISPR model for alternative mRNA splicing, via spliceosome research.
Frequently Asked Questions About alternative mRNA splicing, via spliceosome
What is GO:0000380 alternative mRNA splicing, via spliceosome?
GO:0000380 is the biological process of generating multiple mature mRNAs from one primary transcript by differential exon use through the spliceosome, as defined by QuickGO and supported by spliceosome research.
What genes are involved in alternative mRNA splicing, via spliceosome?
Key genes include core spliceosome components such as SF3B3, SNRPA, and BCAS2, as well as regulators like WAC and many snRNP and SR/hnRNP proteins.
How does the spliceosome carry out alternative splicing?
The spliceosome assembles on the pre-mRNA, recognizes splice sites, and catalyzes two transesterification reactions to remove introns and join exons, with alternative outcomes determined by splice site selection.
Why is alternative splicing important in cancer?
Alternative splicing can produce isoforms that promote proliferation, metastasis, and drug resistance, as shown for SF3B3-regulated mTOR splicing and SNRPA-dependent ERCC1 exon 8 splicing.
What is the role of SF3B3 in alternative splicing?
SF3B3 is a spliceosome component that regulates mTOR alternative splicing and promotes colorectal cancer progression and metastasis.
How does SNRPA affect cisplatin resistance?
m6A-modified SNRPA controls ERCC1 exon 8 alternative splicing, which can induce cisplatin resistance in lung adenocarcinoma.
Is alternative splicing involved in Alzheimer's disease?
Yes, alternative splicing changes have been described in Alzheimer's disease and may affect neuronal function and disease progression.
What methods are used to study alternative mRNA splicing?
Common methods include RNA-seq, long-read isoform sequencing, isoform-specific RT-PCR, minigene assays, spliceosome assembly assays, and imaging of splicing factor condensates.
Can CRISPR be used to study splicing factors?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to test the function of splicing factors and their role in isoform regulation.
What is stepwise exon definition in splicing?
Stepwise exon definition is a model in which recognition of one exon influences adjacent exon decisions, helping explain coordinated alternative splicing outcomes.
Conclusion
GO:0000380 alternative mRNA splicing, via spliceosome is a central biological process that converts a single pre-mRNA into multiple mature mRNA isoforms through spliceosome-mediated exon selection. Its regulation by cis-elements, trans-acting factors, RNA modifications, signaling pathways, and nuclear organization makes it a versatile mechanism for controlling gene expression in health and disease. Dysregulation of this process contributes to cancer progression, chemoresistance, neurodegeneration, and metabolic dysfunction, highlighting its importance as a research and therapeutic focus. Advances in CRISPR-based models and transcriptome-wide methods now allow researchers to dissect the causal roles of specific splicing factors and isoforms with unprecedented precision. By combining knockout, point mutation, knock-in, overexpression, and screening approaches with isoform-level readouts, the field can continue to map the regulatory logic of GO:0000380 and translate these insights into new diagnostic and therapeutic strategies.
References
- 1. Matera AG et al.. 2014. A day in the life of the spliceosome.. Nat Rev Mol Cell Biol 15(2):108-21 PMID: 24452469
- 2. Xu T et al.. 2024. SF3B3-regulated mTOR alternative splicing promotes colorectal cancer progression and metastasis.. J Exp Clin Cancer Res 43(1):126 PMID: 38671459
- 3. Fan W et al.. 2024. m(6)A-Modified SNRPA Controls Alternative Splicing of ERCC1 Exon 8 to Induce Cisplatin Resistance in Lung Adenocarcinoma.. Adv Sci (Weinh) 11(47):e2404609 PMID: 39555714
- 4. Senn KA et al.. 2024. Mechanisms and regulation of spliceosome-mediated pre-mRNA splicing in Saccharomyces cerevisiae.. Wiley Interdiscip Rev RNA 15(4):e1866 PMID: 38972853
- 5. Chen X et al.. 2023. BCAS2 Participates in Insulin Synthesis and Secretion via mRNA Alternative Splicing in Mice.. Endocrinology 165(1) PMID: 37820033
- 6. Biamonti G et al.. 2021. Alternative splicing in Alzheimer's disease.. Aging Clin Exp Res 33(4):747-758 PMID: 31583531
- 7. Kristofori P et al.. 2026. Coordinated alternative splicing decisions via stepwise exon definition.. Nucleic Acids Res 54(9) PMID: 42152680
- 8. Wang J et al.. 2025. Nuclear Condensates of WW Domain-Containing Adaptor With Coiled-Coil Regulate Mitophagy via Alternative Splicing.. Adv Sci (Weinh) 12(10):e2406759 PMID: 39840526
